NCT06454461

Efficacy of Upadacitinib After NECS in Vitiligo

Efficacy of Upadacitinib After Autologous Non-cultured Epidermal Cell Suspension Transplantation in Vitiligo Participants -- a Pilot, Random, Observer Blinded, Comparative Study

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Jilin University · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to investigate the efficacy of upadacitinib after NECS in participants with vitiligo. The main question it aims to answer is: whether the short time use of upadacitinib after NECS will improve NECS efficacy. Participants in the experimental group will receive upadacitinib after NECS, while Participants in the control group will receive NECS only.

Conditions

• Vitiligo

Interventions

Type	Name	Description
DRUG	Upadacitinib 15 MG	Upadacinib 15mg once daily for the 8 weeks after NECS

Timeline

• Start date: 2024-12-04
• Primary completion: 2026-06-01
• Completion: 2029-06-01
• First posted: 2024-06-12
• Last updated: 2024-12-27

Locations

1 site across 1 country: China